Autoimmune thyroid disease: A risk factor for thyroid cancer

Endocrine Practice

Volumn 17, Issue 2, 2011, Pages 201-209

  Azizi, Ghobad ^a   Malchoff, Carl D ^b  

^a Wilmington University   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ASPIRATION BIOPSY; AUTOIMMUNE DISEASE; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK FACTOR; SEX; THYROID CANCER; THYROID DISEASE; THYROID NODULE; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

ADOLESCENT; ADULT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOPSY, FINE-NEEDLE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THYROID DISEASES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 79959264511     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP10123.OR     Document Type: Article

References (23)

1. Coussens LM, Werb Z. Infammation and cancer. Nature. 2002;420:860-867.
2. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting infammation and cancer. Curr Opin Genet Dev. 2008;18:3-10.
3. Guarino V, Castellone MD, Avilla E, Melillo RM. Thyroid cancer and infammation. Mol Cell Endocrinol. 2010;321:94-102.
4. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499. (Pubitemid 34158210)
5. Ott RA, Calandra DB, McCall AR, Shah KH, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma in patients with Hashimoto's thyroiditis and solitary cold nodules. Surgery. 1985;98:1202-1206. (Pubitemid 16104745)
6. Ott RA, McCall AR, McHenry C, et al. The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Am Surg. 1987;53:442-445. (Pubitemid 17122376)
7. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;150:49-52.
8. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery. 1999;126:1070-1076.
9. Larson SD, Jackson LN, Riall TS, et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007;204:764-773. (Pubitemid 46661188)
10. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fne-needle aspiration. J Clin Endocrinol Metab. 2006;91:4295-4301. (Pubitemid 44833401)
11. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87:1941-1946. (Pubitemid 34521470)
12. Kang DY, Kim KH, Kim JM, et al. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid. 2007;17:1030-1038.
13. Kim ES, Lim DJ, Baek KH, et al. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid. 2010;20:885-891.
14. Hegedüs L. Clinical practice: the thyroid nodule. N Engl J Med. 2004;351:1764-1771.
15. Hegedüs L, Bonnema BJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102-132. (Pubitemid 36223282)
16. Mazzaferri EL, de los Santos ET, Rofagha-Keyhani S. Solitary thyroid nodule: diagnosis and management. Med Clin North Am. 1988;72:1177-1211.
17. Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fne-needle aspiration. Thyroid. 1998;8:377-383. (Pubitemid 28252418)
18. Marqusee E, Benson CB, Frates MC, et al. Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med. 2000;133:696-700.
19. Tan GH, Gharib H, Reading CC. Solitary thyroid nodule: comparison between palpation and ultrasonography. Arch Intern Med. 1995;155:2418-2423.
20. Fiore E, Rago T, Provenzale MA, et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer. 2009;16:1251-1260.
21. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809-814. (Pubitemid 351398557)
22. Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg. 2008;32:747-753.
23. Cooper DS, Doherty GM, Haugen BR, et al (American Thyroid Association [ATA] Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [published corrections appear in Thyroid. 2010;20:674-675 and Thyroid. 2010;20:942]. Thyroid. 2009;19:1167-1214.